Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zorevunersen · STK-001

Oligonucleotide (Antisense oligonucleotide) · Gene silencing: SCN1A · developed by Stoke Therapeutics

Phase 3 Most advanced trial
STOK Developer
3 Registered trials

What is Zorevunersen?

Zorevunersen (STK-001) is an antisense oligonucleotide administered by intrathecal injection. It is studied in Dravet syndrome, a severe epilepsy, and is designed to act on SCN1A RNA.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
STK-001
Drug type
Oligonucleotide (Antisense oligonucleotide)
Targets
SCN1A
Mechanism
Gene silencing: SCN1A
Therapy area
Neurology
Developer
Stoke Therapeutics, Inc (STOK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
U4YV46D2DT

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06872125 Phase 3 Dravet Syndrome Active not recruiting STOK
NCT04740476 Phase 2 Dravet Syndrome Active not recruiting STOK
NCT04442295 Phase 1/2 Dravet Syndrome Completed STOK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dravet Syndrome

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the STOK page.

Follow STOK, the company behind Zorevunersen

See STOK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

STOK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.